

8 Literatur

Aiken C, Konner J, Landau NR, Lenburg ME, Trono D (1994). Nef induces CD4 endocytosis: requirement for a critical dileucine motif in the membrane-proximal CD4 cytoplasmic domain. *Cell*. Mar 11;76(5):853-64.

Alkhatib G, Combadiere C, Broder CC, Feng Y, Kennedy PE, Murphy PM, Berger EA (1996). CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. *Science*. Jun 28;272(5270):1955-8.

Anderson PL, Fletcher CV (2001). Clinical Pharmacologic Considerations for HIV-1 Protease Inhibitors. *Curr Infect Dis Rep*. Aug;3(4):381-387.

Apetrei C, Descamps D, Collin G, Loussert-Ajaka I, Damond F, Duca M, Simon F, Brun-Vezinet F (1998). Human immunodeficiency virus type 1 subtype F reverse transcriptase sequence and drug susceptibility. *J Virol*. May;72(5):3534-8.

Appelt K, Bacquet RJ, Bartlett CA, Booth CL, Freer ST, Fuhry MA, Gehring MR, Herrmann SM, Howland EF, Janson CA (1991). Design of enzyme inhibitors using iterative protein crystallographic analysis. *J Med Chem*. Jul;34(7):1925-34. Review.

Arion D, Kaushik N, McCormick S, Borkow G, Parniak MA (1998). Phenotypic mechanism of HIV-1 resistance to 3'-azido-3'-deoxythymidine (AZT): increased polymerization processivity and enhanced sensitivity to pyrophosphate of the mutant viral reverse transcriptase. *Biochemistry*. Nov 10;37(45):15908-17.

Arnold BA, Hepler RW, Keller PM (1998). One-step fluorescent probe product-enhanced reverse transcriptase assay. *Biotechniques*. Jul;25(1):98-106.

Arnold E, Jacobo-Molina A, Nanni RG, Williams RL, Lu X, Ding J, Clark AD Jr, Zhang A, Ferris AL, Clark P, et al (1992). Structure of HIV-1 reverse transcriptase/DNA complex at 7 A resolution showing active site locations. *Nature*. May 7;357(6373):85-9.

Arthur LO, Bess JW Jr, Sowder RC 2nd, Benveniste RE, Mann DL, Chermann JC, Henderson LE (1992). Cellular proteins bound to immunodeficiency viruses: implications for pathogenesis and vaccines. *Science*. Dec 18;258(5090):1935-8.

Ayouba A, Souquieres S, Njinku B, Martin PM, Muller-Trutwin MC, Roques P, Barre-Sinoussi F, Mauclore P, Simon F, Nerrienet E (2000). HIV-1 group N among HIV-1-seropositive individuals in Cameroon. *AIDS*. Nov 10;14(16):2623-5.

Baba M, Pauwels R, Balzarini J, Herdewijn P, De Clercq E, Desmyter J (1987). Ribavirin antagonizes inhibitory effects of pyrimidine 2',3'-dideoxynucleosides but enhances inhibitory effects of purine 2',3'-dideoxynucleosides on replication of human immunodeficiency virus in vitro. *Antimicrob Agents Chemother*. Oct;31(10):1613-7

Back NK, Nijhuis M, Keulen W, Boucher CA, Oude Essink BO, van Kuilenburg AB, van Gennip AH, Berkhout B (1996). Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme. *EMBO J.* Aug 1;15(15):4040-9.

Baldwin ET, Bhat TN, Liu B, Pattabiraman N, Erickson JW (1995). Structural basis of drug resistance for the V82A mutant of HIV-1 proteinase. *Nat Struct Biol.* Mar;2(3):244-9.

Baltimore D (1970). Viral-RNA dependent DNA polymerase: RNA dependent DNA polymerase in virions of RNA tumour viruses. *Nature* 226:1209-11

Barre-Sinoussi F, Chermann JC, Rey F, Nugeyre MT, Chamaret S, Gruest J, Dauguet C, Axler-Blin C, Vezinet-Brun F, Rouzioux C, Rozenbaum W, Montagnier L (1983). Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). *Science.* May 20;220(4599):868-71.

Baxter JD, Mayers DL, Wentworth DN, Neaton JD, Hoover ML, Winters MA, Mannheimer SB, Thompson MA, Abrams DI, Brizz BJ, Ioannidis JP, Merigan TC (2000). A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Bein Community Programs for Clinical Research on AIDS. *AIDS.* Jun 16;14(9):F83-93.

Becker-Pergola G, Kataaha P, Johnston-Dow L, Fung S, Jackson JB, Eshleman SH (2000). Analysis of HIV type 1 protease and reverse transcriptase in antiretroviral drug-naive Ugandan adults. *AIDS Res Hum Retroviruses.* May 20;16(8):807-13.

Berkowitz RD, Goff SP (1994). Analysis of binding elements in the human immunodeficiency virus type 1 genomic RNA and nucleocapsid protein. *Virology.* Jul;202(1):233-46.

Bess JW Jr, Powell PJ, Issaq HJ, Schumack LJ, Grimes MK, Henderson LE, Arthur LO (1992). Tightly bound zinc in human immunodeficiency virus type 1, human T-cell leukemia virus type I, and other retroviruses. *J Virol.* Feb;66(2):840-7.

Bleul CC, Farzan M, Choe H, Parolin C, Clark-Lewis I, Sodroski J, Springer TA (1996). The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. *Nature.* Aug 29;382(6594):829-33.

Blower SM, Aschenbach AN, Gershengorn HB, Kahn JO (2001). Predicting the unpredictable: transmission of drug-resistant HIV. *Nat Med.* Sep;7(9):1016-20.

Boden D, Hurley A, Zhang L, Cao Y, Guo Y, Jones E, Tsay J, Ip J, Farthing C, Limoli K, Parkin N, Markowitz M (1999). HIV-1 drug resistance in newly infected individuals. *JAMA.* Sep 22-29;282(12):1135-41.

Böni J, Pyra H, Schupbach J (1996). Sensitive detection and quantification of particle-associated reverse transcriptase in plasma of HIV-1-infected individuals by the product-enhanced reverse transcriptase (PERT) assay. *J Med Virol.* May;49(1):23-8.

Bowerman B, Brown PO, Bishop JM, Varmus HE (1989). A nucleoprotein complex mediates the integration of retroviral DNA. *Genes Dev.* Apr;3(4):469-78.

Boyer PL, Sarafianos SG, Arnold E, Hughes SH (2002). The M184V mutation reduces the selective excision of zidovudine 5'-monophosphate (AZTMP) by reverse transcriptase of human immunodeficiency virus type 1. *J Virol* Apr;76(7):3248-56

Briones C, Perez-Olmeda M, Rodriguez C, del Romero J, Hertogs K, Soriano V (2001). Primary genotypic and phenotypic HIV-1 resistance in recent seroconverters in Madrid. *J Acquired Immune Defic Syndr*. 26:145-150

Bronstein I, Fortin JJ, Voyta JC, Juo RR, Edwards B, Olesen CE, Lijam N, Kricka LJ (1994). Chemiluminescent reporter gene assays: sensitive detection of the GUS and SEAP gene products. *Biotechniques*. Jul;17(1):172-4, 176-7.

Brown PO, Bowerman B, Varmus HE, Bishop JM (1989). Retroviral integration: structure of the initial covalent product and its precursor, and a role for the viral IN protein. *Proc Natl Acad Sci U S A*. Apr;86(8):2525-9.

Brunn M et al. (1999). Einflußgrößen auf den Krankheitsverlauf der HIV-Infektion-Seokonverterstudie, In: Norbert Brockmeyer et al. (Hrsg.): HIV-Infekt: Epidemiologie, Prävention, Pathogenese, Diagnostik, Therapie, Psycho-Soziologie. Berlin, Heidelberg: Springer, 133-140

Bruno R, Regazzi MB, Ciappina V, Villani P, Sacchi P, Montagna M, Panebianco R, Filice G (2001). Comparison of the plasma pharmacokinetics of lamivudine during twice and once daily administration in patients with HIV. *Clin Pharmacokinet*.;40(9):695-700.

Bryant M, Ratner L (1990). Myristoylation-dependent replication and assembly of human immunodeficiency virus 1. *Proc Natl Acad Sci U S A*. Jan;87(2):523-7.

Bukrinsky MI, Sharova N, Dempsey MP, Stanwick TL, Bukrinskaya AG, Haggerty S, Stevenson M (1992). Active nuclear import of human immunodeficiency virus type 1 preintegration complexes. *Proc Natl Acad Sci U S A*. Jul 15;89(14):6580-4.

Bukrinsky MI, Sharova N, McDonald TL, Pushkarskaya T, Tarpley WG, Stevenson M (1993). Association of integrase, matrix, and reverse transcriptase antigens of human immunodeficiency virus type 1 with viral nucleic acids following acute infection. *Proc Natl Acad Sci U S A*. Jul 1;90(13):6125-9.

Caliendo AM, Savara A, An D, DeVore K, Kaplan JC, D'Aquila RT (1996). Effects of zidovudine-selected human immunodeficiency virus type 1 reverse transcriptase amino acid substitutions on processive DNA synthesis and viral replication. *J Virol*. Apr;70(4):2146-53.

Cameron DW, Heath-Chiozzi M, Danner S, Cohen C, Kravcik S, Maurath C, Sun E, Henry D, Rode R, Potthoff A, Leonard J (1998). Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. The Advanced HIV Disease Ritonavir Study Group. *Lancet*. Feb 21;351(9102):543-9.

Carpenter CC, Cooper DA, Fischl MA, Gatell JM, Gazzard BG, Hammer SM, Hirsch MS, Jacobson DM, Katzenstein DA, Montaner JS, Richman DD, Saag MS, Schechter M, Schooley RT, Thompson MA, Vella S, Yeni PG, Volberding PA (2000). Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel. *JAMA*. 283:381-90

Carr JK, Foley B, Leitner T, Salminen M, Korber BT, McCutchan FE (1998). Reference sequences representing the principal genetic diversity of HIV- 1 in the pandemic. In: *Human Retrovirus and AIDS*. Edited by Los Alamos National Laboratory, Los Alamos NM, Part III.

Carrillo A, Stewart KD, Sham HL, Norbeck DW, Kohlbrenner WE, Leonard JM, Kempf DJ, Molla A (1998). In vitro selection and characterization of human immunodeficiency virus type 1 variants with increased resistance to ABT-378, a novel protease inhibitor. *J Virol.* Sep;72(9):7532-41.

Cassol S, Salas T, Lapointe N, Arella M, Rudnik J, O'Shaughnessy M (1991). Improved detection of HIV-1 envelope sequences using optimized PCR and inosine-substituted primers. *Mol Cell Probes.* Apr;5(2):157-60.

Charneau P, Alizon M, Clavel F (1992). A second origin of DNA plus-strand synthesis is required for optimal human immunodeficiency virus replication. *J Virol.* May;66(5):2814-20.

Charneau P, Mirambeau G, Roux P, Paulous S, Buc H, Clavel F (1994). HIV-1 reverse transcription. A termination step at the center of the genome. *J Mol Biol.* Sep 2;241(5):651-62.

Chen Z, Li Y, Schock HB, Hall D, Chen E, Kuo LC (1995). Three-dimensional structure of a mutant HIV-1 protease displaying cross-resistance to all protease inhibitors in clinical trials. *J Biol Chem.* Sep 15;270(37):21433-6.

Cherrington J, Ganem D (1992). Regulation of polyadenylation in human immunodeficiency virus (HIV): contributions of promoter proximity and upstream sequences. *EMBO J.* Apr;11(4):1513-24.

Choe H, Farzan M, Sun Y, Sullivan N, Rollins B, Ponath PD, Wu L, Mackay CR, LaRosa G, Newman W, Gerard N, Gerard C, Sodroski J (1996). The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. *Cell.* Jun 28;85(7):1135-48.

Chong YH, Schinazi RF, Chu CK (2002). Molecular mechanism of DAPD anti-HIV activity against AZT and 3TC mutants-molecular modeling studies of HIV-1 RT. 9th Conference on Retroviruses and Opportunistic Infections (CROI), Seattle, Abstract GA1464-W

Cingolani A, Antinori A, Rizzo MG, Murri R, Ammassari A, Baldini F, Di Giambenedetto S, Cauda R, De Luca A (2002). Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA). *AIDS.* Feb 15;16(3):369-79.

Coffin JM (1990). Retroviridae and their replication. In: *Fundamental Virology*, ed.: Fields BN, Knipe DM et al. Raven Press, Ltd., New York 1990

Cohen CJ, Hunt S, Sension M, Farthing C, Conant M, Jacobson S, Nadler J, Verbiest W, Hertogs K, Ames M, Rinehart AR, Graham NM (2002). A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy. *AIDS.* Mar 8;16(4):579-88.

Cohen EA, Terwilliger EF, Sodroski JG, Haseltine WA (1988). Identification of a protein encoded by the vpu gene of HIV-1. *Nature.* Aug 11;334(6182):532-4.

Collins KL, Chen BK, Kalams SA, Walker BD, Baltimore D (1998). HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes. *Nature*. Jan 22;391(6665):397-401.

Cote HC, Brumme ZL, Harrigan PR (2001). Human immunodeficiency virus type 1 protease cleavage site mutations associated with protease inhibitor cross-resistance selected by indinavir, ritonavir, and/or saquinavir. *J Virol*. Jan;75(2):589-94

Craig JC, Duncan IB, Hockley D, Grief C, Roberts NA, Mills JS (1991). Antiviral properties of Ro 31-8959, an inhibitor of human immunodeficiency virus (HIV) proteinase. *Antiviral Res*. Dec;16(4):295-305.

Crawford S, Goff SP (1985). A deletion mutation in the 5' part of the pol gene of Moloney murine leukemia virus blocks proteolytic processing of the gag and pol polyproteins. *J Virol*. Mar;53(3):899-907.

Cullen BR (1991). Regulation of HIV-1 gene expression. *FASEB Journal* 5(10), 2361-8

Dagleish AG, Beverley PC, Clapham PR, Crawford DH, Greaves MF, Weiss RA (1984). The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. *Nature*. Dec 20-1985 Jan 2;312(5996):763-7.

D'Aquila RT, Schapiro JM and the Drug Resistance Mutation Group (2001) Drug resistance mutations Update International AIDS Society-USA. *Topics in HIV Medicine* 9(6):21-3

De Ronde A, Bouwhuis D, de Rooy ER et al. (1998). Fitness of HIV-1 RT mutant: is Muller's ratchet operational ? *XII International Congress on AIDS*, Geneva, Switzerland.

Debyser Z, De Vreese K, Pauwels R, Yamamoto N, Anne J, De Clercq E, Desmyter J (1992). Differential inhibitory effects of TIBO derivatives on different strains of simian immunodeficiency virus. *J Gen Virol*. Jul;73 (Pt 7):1799-804.

Delta Coordinating Committee (1996). A randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Delta Coordinating Committee. *Lancet*. Aug 3;348(9023):283-91.

Deng H, Liu R, Ellmeier W, Choe S, Unutmaz D, Burkhart M, Di Marzio P, Marmon S, Sutton RE, Hill CM, Davis CB, Peiper SC, Schall TJ, Littman DR, Landau NR (1996). Identification of a major co-receptor for primary isolates of HIV-1. *Nature*. Jun 20;381(6584):661-6.

Descamps D, Apetrei C, Collin G, Damond F, Simon F, Brun-Vezinet F (1998). Naturally occurring decreased susceptibility of HIV-1 subtype G to protease inhibitors. *AIDS*. Jun 18;12(9):1109-11.

Descamps D, Collin G, Letourneur F, Apetrei C, Damond F, Loussert-Ajaka I, Simon F, Saragosti S, Brun-Vezinet F (1997). Susceptibility of human immunodeficiency virus type 1 group O isolates to antiretroviral agents: in vitro phenotypic and genotypic analyses. *J Virol*. Nov;71(11):8893-8.

DeZazzo JD, Scott JM, Imperiale MJ (1992). Relative roles of signals upstream of AAUAAA and promoter proximity in regulation of human immunodeficiency virus type 1 mRNA 3' end formation. *Mol Cell Biol.* Dec;12(12):5555-62.

Ding J, Das K, Moereels H, Koymans L, Andries K, Janssen PA, Hughes SH, Arnold E (1995). Structure of HIV-1 RT/TIBO R 86183 complex reveals similarity in the binding of diverse nonnucleoside inhibitors. *Nat Struct Biol.* May;2(5):407-15.

Doms RW, Peiper SC (1997). Unwelcomed guests with master keys: how HIV uses chemokine receptors for cellular entry. *Virology.* Sep 1;235(2):179-90. Review.

Doranz BJ, Rucker J, Yi Y, Smyth RJ, Samson M, Peiper SC, Parmentier M, Collman RG, Doms RW (1996). A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. *Cell.* Jun 28;85(7):1149-58.

Dorfman T, Mammano F, Haseltine WA, Gottlinger HG (1994). Role of the matrix protein in the virion association of the human immunodeficiency virus type 1 envelope glycoprotein. *J Virol.* Mar;68(3):1689-96.

Doyle C, Strominger JL (1987). Interaction between CD4 and class II MHC molecules mediates cell adhesion. *Nature.* Nov 19-25;330(6145):256-9.

Doyon L, Croteau G, Thibeault D, Poulin F, Pilote L, Lamarre D (1996). Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors. *J Virol.* Jun;70(6):3763-9.

Dragic T, Litwin V, Allaway GP, Martin SR, Huang Y, Nagashima KA, Cayanan C, Maddon PJ, Koup RA, Moore JP, Paxton WA (1996). HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. *Nature.* Jun 20;381(6584):667-73.

DuBridges RB, Tang P, Hsia HC, Leong PM, Miller JH, Calos MP (1987). Analysis of mutation in human cells by using an Epstein-Barr virus shuttle system. *Mol Cell Biol.* Jan;7(1):379-87.

Dueweke TJ, Kezdy FJ, Waszak GA, Deibel MR Jr, Tarpley WG (1992). The binding of a novel bisheteroarylpiperazine mediates inhibition of human immunodeficiency virus type 1 reverse transcriptase. *J Biol Chem.* Jan 5;267(1):27-30.

Durant J, Clevenbergh P, Halfon P, Delgiudice P, Porsin S, Simonet P, Montagne N, Boucher CA, Schapiro JM, Dellamonica P (1999). Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. *Lancet.* Jun 26;353(9171):2195-9.

Earl PL, Doms RW, Moss B (1990). Oligomeric structure of the human immunodeficiency virus type 1 envelope glycoprotein. *Proc Natl Acad Sci USA.* Jan;87(2):648-52.

Endres MJ, Clapham PR, Marsh M, Ahuja M, Turner JD, McKnight A, Thomas JF, Stoebenau-Haggarty B, Choe S, Vance PJ, Wells TN, Power CA, Sutterwala SS, Doms RW, Landau NR, Hoxie JA (1996). CD4-independent infection by HIV-2 is mediated by fusin/CXCR4. *Cell.* Nov 15;87(4):745-56.

Epidemiologisches Bulletin, Aktuelle Daten und Informationen zu Infektionskrankheiten und Public Health. Robert Koch-Institut. 15.Mai 2002 Sonderausgabe A

Erickson JW, Gulnik SV, Markowitz M. Protease inhibitors: resistance, cross-resistance, fitness and the choice of initial and salvage therapies (1999). *AIDS*;13 Suppl A:S189-204. Review.

Erickson-Viitanen S, Schinazi RF, Mellors J, Geleziunas R, Trainor G, Wu JT., Gallagher K, Klabe R, Otto M, Pierce M, Martin DE (2002). DPC 817: A Cytidine Nucleoside Analog with activity against AZT- and 3TC-resistant viral variants. 9th Conference on Retroviruses and Opportunistic Infections (CROI), Seattle, Abstract 385-T

Esnouf R, Ren J, Ross C, Jones Y, Stammers D, Stuart D (1995). Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors. *Nat Struct Biol*. Apr;2(4):303-8.

Farnet CM, Haseltine WA (1991). Determination of viral proteins present in the human immunodeficiency virus type 1 preintegration complex. *J Virol*. Apr;65(4):1910-5.

Felsenstein J (1993). PHYLIP (Phylogeny Interference Package) version 3.5c. Distributed by the author. Department of Genetics, University of Washington Seattle

Feng JY, Anderson KS (1999). Mechanistic studies examining the efficiency and fidelity of DNA synthesis by the 3TC-resistant mutant (184V) of HIV-1 reverse transcriptase. *Biochemistry*. Jul 20;38(29):9440-8.

Feng S, Holland EC (1988). HIV-1 tat trans-activation requires the loop sequence within tar. *Nature*. Jul 14;334(6178):165-7

Feng Y, Broder CC, Kennedy PE, Berger EA (1996). HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. *Science*. May 10;272(5263):872-7.

Fischl MA, Richman DD, Grieco MH, Gottlieb MS, Volberding PA, Laskin OL, Leedom JM, Groopman JE, Mildvan D, Schooley RT, et al (1987). The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. *N Engl J Med*. Jul 23;317(4):185-91.

Fischl MA, Richman DD, Hansen N, Collier AC, Carey JT, Para MF, Hardy WD, Dolin R, Powderly WG, Allan JD, et al (1990). The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials Group. *Ann Intern Med*. May 15;112(10):727-37.

Fisher AG, Ensoli B, Ivanoff L, Chamberlain M, Petteway S, Ratner L, Gallo RC, Wong-Staal F (1987). The sor gene of HIV-1 is required for efficient virus transmission in vitro. *Science*. Aug 21;237(4817):888-93.

Fletcher CV (1999). Pharmacologic considerations for therapeutic success with antiretroviral agents. *Ann Pharmacother*. Sep;33(9):989-95. Review.

Franke EK, Yuan HE, Luban J (1994). Specific incorporation of cyclophilin A into HIV-1 virions. *Nature*. Nov 24;372(6504):359-62.

Furfine ES, Reardon JE (1991). Reverse transcriptase RNase H from the human immunodeficiency virus. Relationship of the DNA polymerase and RNA hydrolysis activities. *J Biol Chem*. 266(1):406-12.]

Furman PA, Fyfe JA, St Clair MH, Weinhold K, Rideout JL, Freeman GA, Lehrman SN, Bolognesi DP, Broder S, Mitsuya H, et al (1986). Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase. *Proc Natl Acad Sci U S A*. Nov;83(21):8333-7.

Gallay P, Swingler S, Aiken C, Trono D (1995). HIV-1 infection of nondividing cells: C-terminal tyrosine phosphorylation of the viral matrix protein is a key regulator. *Cell*. Feb 10;80(3):379-88.

Gao F, Bailes E, Robertson DL, Chen Y, Rodenburg CM, Michael SF, Cummins LB, Arthur LO, Peeters M, Shaw GM, Sharp PM, Hahn BH (1999). Origin of HIV-1 in the chimpanzee Pan troglodytes troglodytes. *Nature*. Feb 4;397(6718):436-41.

Gao F, Vidal N, Li Y, Trask SA, Chen Y, Kostrikis LG, Ho DD, Kim J, Oh MD, Choe K, Salminen M, Robertson DL, Shaw GM, Hahn BH, Peeters M (2001). Evidence of two distinct subtypes within the HIV-1 subtype A radiation. *AIDS Res Hum Retroviruses*. May 20;17(8):675-88.

Gao Q, Gu Z, Parniak MA, Cameron J, Cammack N, Boucher C, Wainberg MA (1993). The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine confers high-level resistance to the (-) enantiomer of 2',3'-dideoxy-3'-thiacytidine. *Antimicrob Agents Chemother*. Jun;37(6):1390-2.

Garcia-Lerma JG, Nidtha S, Blumoff K, Weinstock H, Heneine W (2001). Increased ability for selection of zidovudine resistance in a distinct class of wild-type HIV-1 from drug-naive persons. *Proc Natl Acad Sci U S A*. Nov 20;98(24):13907-12.

Gazzard B, Pozniak A, Arasteh K, Staszewski S, Rozenbaum W, Yeni P, van 't Klooster G, De K, Dier M, Peeters M, de Béthune P, Graham N, Pauwels R (2002). TMC125, a next-generation NNRTI, demonstrates high potency after 7 days therapy in treatment-experienced HIV-1-infected individuals with phenotypic NNRTI resistance. 9th Conference on Retroviruses and Opportunistic Infections (CROI), Seattle, Abstract 4

Gelderblom HR (1991). Assembly and morphology of HIV: potential effect of structure on viral function [editorial]. *AIDS* 5(6):617-37

Gelderblom HR, Hausmann EH, Ozel M, Pauli G, Koch MA (1987). Fine structure of human immunodeficiency virus (HIV) and immunolocalization of structural proteins. *Virology*. Jan;156(1):171-6.

Gendelman HE, Orenstein JM, Baca LM, Weiser B, Burger H, Kalter DC, Meltzer MS (1989). The macrophage in the persistence and pathogenesis of HIV infection. *AIDS*. Aug;3(8):475-95. Review.

Gerondelis P, Archer RH, Palaniappan C, Reichman RC, Fay PJ, Bambara RA, Demeter LM (1999). The P236L delavirdine-resistant human immunodeficiency virus type 1 mutant is replication defective and demonstrates alterations in both RNA 5'-end- and DNA 3'-end-directed RNase H activities. *J Virol.* Jul;73(7):5803-13.

Gözl J (1999) In: *HIV und AIDS, Praxis der Beratung und Behandlung*. Eds. Gözl, Mayr, Heise, Urban & Fischer S. 106-30

Gomes P, Diogo I, Gonçalves MF, Carvalho P, Cabanas J, Lobo MC, Camacho R (2002). Different pathways to Nelfinavir genotypic resistance in HIV-1 subtypes B and G. 9th Conference on Retroviruses and Opportunistic Infections (CROI), Seattle, Abstract 46

Goncalves J, Jallepalli P, Gabuzda DH (1994). Subcellular localization of the Vif protein of human immunodeficiency virus type 1. *J Virol.* Feb;68(2):704-12.

Goncalves J, Shi B, Yang X, Gabuzda D (1995). Biological activity of human immunodeficiency virus type 1 Vif requires membrane targeting by C-terminal basic domains. *J Virol.* Nov;69(11):7196-204.

Goodrich DW, Duesberg PH (1990). Retroviral recombinant during reverse transcription. *Proc Natl Acad Sci USA* 87:2050-56

Götte M, Arion D, Parniak MA, Wainberg MA (2000). The M184V mutation in the reverse transcriptase of human immunodeficiency virus type 1 impairs rescue of chain-terminated DNA synthesis. *J Virol.* Apr;74(8):3579-85.

Graham FL, Smiley J, Russel WC, Nairn R (1977). Characteristics of a human cell line transformed by DNA from human adenovirus type 5. *J Gen Virol.* Jul;36(1):59-74

Grant RM, Kahn J, Warmerdam M, Liu L, Petropoulos CJ, Hellmann N S, Hecht F (2002). Transmission and Transmissibility of Drug Resistant HIV-1. 9th Conference on Retroviruses and Opportunistic Infections (CROI), Seattle, Abstract CA368-M

Gröschel B, Cinatl J, Cinatl J Jr (1997). Viral and cellular factors for resistance against antiretroviral agents. *Intervirology*;40(5-6):400-7. Review.

Grund C (1991). Quantifizierung von Primaten-Immundefizienzviren: Untersuchungen zur Titration, Inaktivierung und Neutralisation von SIV und HIV. Inaugural-Dissertation, Freie Universität Berlin, Journal-Nr. 1572

Gulick RM, Mellors JW, Havlir D, Eron JJ, Gonzalez C, McMahon D, Richman DD, Valentine FT, Jonas L, Meibohm A, Emini EA, Chodakewitz JA (1997). Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. *N Engl J Med.* Sep 11;337(11):734-9.

Gürtler LG, Zekeng L, Tsague JM, van Brunn A, Afane Ze E, Eberle J, Kaptue L (1996). HIV-1 subtype O: epidemiology, pathogenesis, diagnosis, and perspectives of the evolution of HIV. *Arch Virol Suppl.*11:195-202. Review.

Gustchina A, Weber IT (1990). Comparison of inhibitor binding in HIV-1 protease and in non-viral aspartic proteases: the role of the flap. *FEBS Lett.* Aug 20;269(1):269-72.

Guy B, Geist M, Dott K, Spehner D, Kieny MP, Lecocq JP (1991). A specific inhibitor of cysteine proteases impairs a Vif-dependent modification of human immunodeficiency virus type 1 Env protein. *J Virol.* Mar;65(3):1325-31.

Hahn BH, Shaw GM, De Cock KM, Sharp PM (2000). AIDS as a zoonosis: scientific and public health implications. *Science.* 287(5453):607-14.

Hammer SM, Katzenstein DA, Hughes MD, Gundacker H, Schooley RT, Haubrich RH, Henry WK, Lederman MM, Phair JP, Niu M, Hirsch MS, Merigan TC (1996). A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team. *N Engl J Med.* Oct 10;335(15):1081-90.

Harrigan PR, Bloor S, Larder BA (1998). Relative replicative fitness of zidovudine-resistant human immunodeficiency virus type 1 isolates in vitro. *J Virol.* May;72(5):3773-8.

Harris M (1999). HIV: a new role for Nef in the spread of HIV. *Curr Biol.* Jun 17;9(12):R459-61. Review.

Harzic M, Pellegrin I, Deveau C, Chaix ML, Dubeaux B, Garrigue I, Ngo N, Rouzioux C, Goujard C, Hoen B, Sereni D, Delfraissy JF, Meyer L (2002). Genotypic drug resistance during HIV-1 primary infection in France (1996-1999): frequency and response to treatment. *AIDS.* Mar 29;16(5):793-6.

He J, Chen Y, Farzan M, Choe H, Ohagen A, Gartner S, Busciglio J, Yang X, Hofmann W, Newman W, Mackay CR, Sodroski J, Gabuzda D (1997). CCR3 and CCR5 are co-receptors for HIV-1 infection of microglia. *Nature.* Feb 13;385(6617):645-9.

He J, Choe S, Walker R, Di Marzio P, Morgan DO, Landau NR (1995). Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity. *J Virol.* Nov;69(11):6705-11.

Hecht FM, Grant RM, Petropoulos CJ, Dillon B, Chesney MA, Tian H, Hellmann NS, Bandrapalli NI, Digilio L, Branson B, Kahn JO (1998). Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors. *N Engl J Med.* Jul 30;339(5):307-11.

Heinzinger NK, Bukinsky MI, Haggerty SA, Ragland AM, Kewalramani V, Lee MA, Gendelman HE, Ratner L, Stevenson M, Emerman M (1994). The Vpr protein of human immunodeficiency virus type 1 influences nuclear localization of viral nucleic acids in nondividing host cells. *Proc Natl Acad Sci U S A.* Jul 19;91(15):7311-5.

Henderson LE, Bowers MA, Sowder RC 2nd, Serabyn SA, Johnson DG, Bess JW Jr, Arthur LO, Bryant DK, Fenselau C (1992). Gag proteins of the highly replicative MN strain of human immunodeficiency virus type 1: posttranslational modifications, proteolytic processings, and complete amino acid sequences. *J Virol.* Apr;66(4):1856-65.

Henry K (2000). The case for more cautious, patient-focused antiretroviral therapy. *Ann Intern Med.* 132:306-11

Hirsch MS, Conway B, D'Aquila RT et al. (2000). Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. *JAMA*. 283:2417-2426

Hirsch MS, Conway B, D'Aquila RT, Johnson VA, Brun-Vezinet F, Clotet B, Demeter LM, Hammer SM, Jacobsen DM, Kuritzkes DR, Loveday C, Mellors JW, Vella S, Richman DD (1998). Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society--USA Panel. *JAMA*. Jun 24;279(24):1984-91. Review.

HIV/AIDS-Halbjahresbericht II/2000. Bericht des AIDS-Zentrums im Robert Koch-Institut über aktuelle epidemiologische Daten in Deutschland. *Epidemiologisches Bulletin* Sonderausgabe A/2000:1-16

Hogg R, Wood E, Yip B, O'Shaughnessy MV, Montaner JSG (2002). Physician Experience is an Important and Independent Determinant of HIV-Related Mortality among Person Initiating Antiretroviral Therapy. 9th Conference on Retroviruses and Opportunistic Infections (CROI), Seattle, Abstract 749-W

Holland PM, Abramson RD, Watson R, Gelfand DK (1991). Detection of specific polymerase chain reaction products by utilising the 5'→3'-Exonuclease activity of *Thermus aquaticus* DNA Polymerase. *Proc Natl Acad Sci USA* 88(16):7276-80

Horuk R (1994). Molecular properties of the chemokine receptor family. *Trends Pharmacol Sci*. May;15(5):159-65. Review.

Hostomsky Z, Hostomska Z, Fu TB, Taylor J (1992). Reverse transcriptase of human immunodeficiency virus type 1: functionality of subunits of the heterodimer in DNA synthesis. *J Virol*. May;66(5):3179-82.

Hsiou Y, Ding J, Das K, Clark AD Jr, Hughes SH, Arnold E (1996). Structure of unliganded HIV-1 reverse transcriptase at 2.7 Å resolution: implications of conformational changes for polymerization and inhibition mechanisms. *Structure*. Jul 15;4(7):853-60.

Hu WS, Temin HM (1990). Retroviral recombination and reverse transcription. *Science*. Nov 30;250(4985):1227-33.

Iversen AK, Shafer RW, Wehrly K, Winters MA, Mullins JI, Chesebro B, Merigan TC (1996). Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy. *J Virol*. Feb;70(2):1086-90.

Jacobo-Molina A, Arnold E (1991). HIV reverse transcriptase structure-function relationships. *Biochemistry*. Jul 2;30(26):6351-6. Review.

Jacobo-Molina A, Ding J, Nanni RG, Clark AD Jr, Lu X, Tantillo C, Williams RL, Kamer G, Ferris AL, Clark P, et al (1993). Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 Å resolution shows bent DNA. *Proc Natl Acad Sci U S A*. Jul 1;90(13):6320-4.

- Javaherian K**, Langlois AJ, McDanal C, Ross KL, Eckler LI, Jellis CL, Profy AT, Rusche JR, Bolognesi DP, Putney SD, et al (1989). Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein. *Proc Natl Acad Sci U S A*. Sep;86(17):6768-72.
- Jones Ka**, Kadonaga JT, Luciw PA, Tjian (1986). Activation of the AIDS retrovirus promoter by cellular transcription factor, Sp1. *Science* 232:755-9
- Jowett JB**, Planelles V, Poon B, Shah NP, Chen ML, Chen IS (1995). The human immunodeficiency virus type 1 vpr gene arrests infected T cells in the G2 + M phase of the cell cycle. *J Virol*. Oct;69(10):6304-13.
- Kacian DL**, Watson KF, Burny A, Spiegelman S (1971). Purification of the DNA polymerase of avian myeloblastosis virus. *Biochim Biophys Acta*. Sep 24;246(3):365-83.
- Kaerber G** (1931). Beitrag zur kollektiven Behandlung pharmakologischer Reihenversuche. *Arch. exp. Pathol. Pharmacol.* 162:480
- Karageorgos L**, Li P, Burrell CJ (1995). Stepwise analysis of reverse transcription in a cell-to-cell human immunodeficiency virus infection model: kinetics and implications. *J Gen Virol*. Jul;76 (Pt 7):1675-86.
- Karczewski MK**, Strebel K (1996). Cytoskeleton association and virion incorporation of the human immunodeficiency virus type 1 Vif protein. *J Virol*. Jan;70(1):494-507.
- Kellam P**, Boucher CAB, Larder BA (1992). Fifth mutation in human immunodeficiency virus type 1 contributes to the development of high-level resistance to zidovudine. *Proc Natl Acad Sci USA*. 89:1934-8
- Kempf DJ**, Isaacson JD, King MS, Brun SC, Xu Y, Real K, Bernstein BM, Japour AJ, Sun E, Rode RA (2001). Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patients. *J Virol*. Aug;75(16):7462-9.
- Kempf DJ**, Marsh KC, Denissen JF, McDonald E, Vasavanonda S, Flentge CA, Green BE, Fino L, Park CH, Kong XP, et al (1995). ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. *Proc Natl Acad Sci U S A*. Mar 28;92(7):2484-8.
- Keulen W**, de Graaf L, Berkhout B, Boucher C (1998). Evolution of zidovudine resistance mutations *in vivo* can be explained by differences in viral fitness (Abstract). *Antiviral Therapy*. 3:24
- Kiermayr S**, Skern T (2000). A bacterial screening system of the human immunodeficiency virus type I (HIV-1) protease. Frühjahrstagung der Gesellschaft für Virologie (GfV), Wien, Abstract 6P21
- Kinoshita T** (1991). Biology of complement: the overture. *Immunol Today*. Sep;12(9):291-5. Review.

Klatzmann D, Champagne E, Chamaret S, Gruet J, Guetard D, Hercend T, Gluckman JC, Montagnier L (1984). T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV. *Nature*. Dec 20-1985 Jan 2;312(5996):767-8.

Klimkait T, Strebel K, Hoggan MD, Martin MA, Orenstein JM (1990). The human immunodeficiency virus type 1-specific protein vpu is required for efficient virus maturation and release. *J Virol*. Feb;64(2):621-9.

Kohlstaedt LA, Wang J, Rice PA, Friedman JM, Steitz TA (1992a). Crystal structure at 3.5 Å resolution of HIV-1 reverse transcriptase complexed with an inhibitor. *Science* 256:1783-90

Kohlstaedt LA, Steitz TA (1992b). Reverse transcriptase of human immunodeficiency virus can use either human tRNA(3Lys) or Escherichia coli tRNA(2Gln) as a primer in an in vitro primer-utilization assay. *Proc Natl Acad Sci U S A*. Oct 15;89(20):9652-6.

Krakower JM, Barbacid M, Aaronson SA (1977). Radioimmunoassay for mammalian type C viral reverse transcriptase. *J Virol*. May;22(2):331-9.

Kroeger Smith MB, Rouzer CA, Taneyhill LA, Smith NA, Hughes SH, Boyer PL, Janssen PA, Moereels H, Koymans L, Arnold E, et al (1995). Molecular modeling studies of HIV-1 reverse transcriptase nonnucleoside inhibitors: total energy of complexation as a predictor of drug placement and activity. *Protein Sci*. Oct;4(10):2203-22.

Kücherer C, Fischer K (2001). Die HIV-Serokonverterstudie - Einflussfaktoren auf die Progression der HIV-Erkrankung, Verbreitung von HIV-1 Subtypen und Übertragung resistenter Viren in Deutschland. *Retrovirus Bulletin* 3:1-5

Lalezari J, DeJesus E, Northfelt D, Richmond G, Delehanty J, DeMasi R, Salgo M (2002). A week 48 assessment of a randomized, controlled, open-label Phase II Trial (T20-206) evaluating 3 doses of T-20 in PI-experienced, NNRTI-naïve patients infected with HIV-1. 9th Conference on Retroviruses and Opportunistic Infections (CROI), Seattle, Abstract 418-W

Lapatto R, Blundell T, Hemmings A, Overington J, Wilderspin A, Wood S, Merson JR, Whittle PJ, Danley DE, Geoghegan KF, et al (1989). X-ray analysis of HIV-1 proteinase at 2.7 Å resolution confirms structural homology among retroviral enzymes. *Nature*. Nov 16;342(6247):299-302.

Larder BA, Darby G, Richman DD (1989). HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. *Science*. Mar 31;243(4899):1731-4.

Larder BA, Kemp SD, Harrigan PR (1995). Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. *Science*. Aug 4;269(5224):696-9.

Larder BA, Kohli A, Kellam P, Kemp SD, Kronick M, Henfrey RD (1993). Quantitative detection of HIV-1 drug resistance mutations by automated DNA sequencing. *Nature*. Oct 14;365(6447):671-3.

Lasky LA, Nakamura G, Smith DH, Fennie C, Shimasaki C, Patzer E, Berman P, Gregory T, Capon DJ (1987). Delineation of a region of the human immunodeficiency virus type 1 gp120 glycoprotein critical for interaction with the CD4 receptor. *Cell*. Sep 11;50(6):975-85.

- Lavallee C**, Yao XJ, Ladha A, Gottlinger H, Haseltine WA, Cohen EA (1994). Requirement of the Pr55gag precursor for incorporation of the Vpr product into human immunodeficiency virus type 1 viral particles. *J Virol.* Mar;68(3):1926-34.
- Le Grice SF**, Naas T, Wohlgensinger B, Schatz O (1991). Subunit-selective mutagenesis indicates minimal polymerase activity in heterodimer-associated p51 HIV-1 reverse transcriptase. *EMBO J.* Dec;10(12):3905-11.
- Leahy DJ**, Axel R, Hendrickson WA (1992). Crystal structure of a soluble form of the human T cell coreceptor CD8 at 2.6 Å resolution. *Cell.* Mar 20;68(6):1145-62.
- Lin TS**, Chen MS, McLaren C, Gao YS, Ghazzouli I, Prusoff WH (1987). Synthesis and antiviral activity of various 3'-azido, 3'-amino, 2',3'-unsaturated, and 2',3'-dideoxy analogues of pyrimidine deoxyribonucleosides against retroviruses. *J Med Chem.* Feb;30(2):440-4.
- Little SJ** (2001). Is transmitted drug resistance in HIV on the rise? It seems so. *BMJ.* May 5;322(7294):1074-5.
- Little SJ**, Daar ES, D'Aquila RT et al. (1999). Reduced antiretroviral drug susceptibility among patients with primary HIV infection. *JAMA* 282:1142-9
- Livak KJ**, Flood SJ, Marmaro J, Giusti W, Deetz K (1995). Oligonucleotides with fluorescent dyes at opposite ends provide a quenched probe system useful for detecting PCR product and nucleic acids hybridization. *PCR Methods Appl.* 4(6):357-62
- Loveday C** (2001). Nukleosid Reverse Transkriptase Inhibitor Resistance. *JAIDS* 26:S10-S24
- Lu YL**, Spearman P, Ratner L (1993). Human immunodeficiency virus type 1 viral protein R localization in infected cells and virions. *J Virol.* Nov;67(11):6542-50.
- Lugert R**, Konig H, Kurth R, Tonje RR (1996). Specific suppression of false-positive signals in the product-enhanced reverse transcriptase assay. *Biotechniques* Feb; 20(2):210-7
- Maddon PJ**, Dalglish AG, McDougal JS, Clapham PR, Weiss RA, Axel R (1986). The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain. *Cell.* Nov 7;47(3):333-48.
- Mammano F**, Petit C, Clavel F (1998). Resistance-associated loss of viral fitness in human immunodeficiency virus type 1: phenotypic analysis of protease and gag coevolution in protease inhibitor-treated patients. *J Virol.* Sep;72(9):7632-7.
- Martinez-Picado J**, Savara AV, Sutton L, D'Aquila RT (1999). Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1. *J Virol.* May;73(5):3744-52.
- Marx JL** (1989). Drug-resistant strains of AIDS virus found. *Science.* Mar 24;243(4898):1551-2.
- McCune JM**, Rabin LB, Feinberg MB, Lieberman M, Kosek JC, Reyes GR, Weissman IL (1988). Endoproteolytic cleavage of gp160 is required for the activation of human immunodeficiency virus. *Cell.* Apr 8;53(1):55-67.

McDougal JS, Maddon PJ, Dalgleish AG, Clapham PR, Littman DR, Godfrey M, Maddon DE, Chess L, Weiss RA, Axel R (1986). The T4 glycoprotein is a cell-surface receptor for the AIDS virus. *Cold Spring Harb Symp Quant Biol.*;51 Pt 2:703-11.

Means RE, Greenough T, Desrosiers RC (1997). Neutralization Sensitivity of cell culture-passaged Simian Immunodeficiency Virus. *J Virol.* Oct;71(10):7895-7902

Mellors JW, Hertogs K, Peeters F, Lanier R, Miller V, Graham N, Larder B, Stoffels P, Pauwels R (1998). Susceptibility of Clinical HIV-1 Isolates to 1592U89 *CROI* Chicago abstract 687

Meyer PR, Matsuura SE, So AG, Scott WA (1998). Unblocking of chain-terminated primer by HIV-1 reverse transcriptase through a nucleotide-dependent mechanism. *Proc Natl Acad Sci U S A.* Nov 10;95(23):13471-6.

Michaels FH, Hattori N, Gallo RC, Franchini G (1993). The human immunodeficiency virus type 1 (HIV-1) vif protein is located in the cytoplasm of infected cells and its effect on viral replication is equivalent in HIV-2. *AIDS Res Hum Retroviruses.* Oct;9(10):1025-30.

Miller M, Johnson A, Isaacson E, Margot N. Genotypic analyses and HIV RNA responses in patients after 96 weeks of tenofovir DF (TDF) therapy. Program and abstracts of The 1st IAS Conference on HIV Pathogenesis and Treatment; July 8-11, 2001; Buenos Aires, Argentina. Abstract 128.

Miller M, Schneider J, Sathyanarayana BK, Toth MV, Marshall GR, Clawson L, Selk L, Kent SB, Wlodawer A (1989). Structure of complex of synthetic HIV-1 protease with a substrate-based inhibitor at 2.3 Å resolution. *Science.* Dec 1;246(4934):1149-52.

Miller MD, Lamy PD, Fuller MD, Mulato AS, Margot NA, Cihlar T, Cherrington JM (1998). Human immunodeficiency virus type 1 reverse transcriptase expressing the K70E mutation exhibits a decrease in specific activity and processivity. *Mol Pharmacol.* Aug;54(2):291-7.

Miller V, Ait-Khaled M, Stone C, Griffin P, Mesogiti D, Cutrell A, Harrigan R, Staszewski S, Katlama C, Pearce G, Tisdale M (2000). HIV-1 reverse transcriptase (RT) genotype and susceptibility to RT inhibitors during abacavir monotherapy and combination therapy. *AIDS.* Jan 28;14(2):163-71.

Miller V, Stark T, Loeliger AE, Lange JM (2002). The impact of the M184V substitution in HIV-1 reverse transcriptase on treatment response. *HIV Med.* Apr;3(2):135-145.

Mitsuya H, Broder S (1987). Strategies for antiviral therapy in AIDS. *Nature.* Feb 26-Mar 4;325(6107):773-8. Review.

Mitsuya H, Weinhold KJ, Furman PA, St Clair MH, Lehrman SN, Gallo RC, Bolognesi D, Barry DW, Broder S (1985). 3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. *Proc Natl Acad Sci U S A.* Oct;82(20):7096-100.

- Modrow S**, Falke D (1998). Molekulare Virologie, Spektrum Akademischer Verlag
- Moelling K** (1974). Characterization of reverse transcriptase and RNase H from friend-murine leukemia virus. *Virology*. Nov;62(1):46-59
- Molla A**, Vasavanonda S, Kumar G, Sham HL, Johnson M, Grabowski B, Denissen JF, Kohlbrenner W, Plattner JJ, Leonard JM, Norbeck DW, Kempf DJ (1998). Human serum attenuates the activity of protease inhibitors toward wild-type and mutant human immunodeficiency virus. *Virology*. Oct 25;250(2):255-62.
- Mouton Y**, Alfandari S, Valette M, Cartier F, Dellamonica P, Humbert G, Lang JM, Massip P, Mechali D, Leclercq P, Modai J, Portier H (1997). Impact of protease inhibitors on AIDS-defining events and hospitalizations in 10 French AIDS reference centres. Federation National des Centres de Lutte contre le SIDA. *AIDS*. Oct;11(12):F101-5.
- Murphy PM** (1996). Chemokine receptors: structure, function and role in microbial pathogenesis. *Cytokine Growth Factor Rev*. Jun;7(1):47-64. Review.
- Nabel G**, Baltimore D (1987). An iducible transcription factor activates expression of human immunodeficiency virus in T-cells. *Nature* 326:711-3
- Naugler WE**, Yong FH, Carey VJ, Dragavon JA, Coombs RW, Frenkel LM (2002). T69D/N pol mutation, human immunodeficiency virus type 1 RNA levels, and syncytium-inducing phenotype are associated with CD4 cell depletion during didanosine therapy. *J Infect Dis*. Feb 15;185(4):448-55.
- Navia MA**, Fitzgerald PM, McKeever BM, Leu CT, Heimbach JC, Herber WK, Sigal IS, Darke PL, Springer JP (1989). Three-dimensional structure of aspartyl protease from human immunodeficiency virus HIV-1. *Nature*. Feb 16;337(6208):615-20.
- Neumann M**, Harrison J, Saltarelli M, Hadziyannis E, Erfle V, Felber BK, Pavlakis GN (1994). Splicing variability in HIV type 1 revealed by quantitative RNA polymerase chain reaction. *AIDS Res Hum Retroviruses*. Nov;10(11):1531-42.
- Nijhuis M**, Deeks S, Boucher C (2001). Implications of antiretroviral resistance on viral fitness. *Curr Opin Infect Dis*. Feb;14(1):23-8.
- Nijhuis M**, Schuurman R, de Jong D, Erickson J, Gustchina E, Albert J, Schipper P, Gulnik S, Boucher CA (1999). Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy. *AIDS*. Dec 3;13(17):2349-59.
- Oberlin E**, Amara A, Bachelier F, Bessia C, Virelizier JL, Arenzana-Seisdedos F, Schwartz O, Heard JM, Clark-Lewis I, Legler DF, Loetscher M, Baggiolini M, Moser B (1996). The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1. *Nature*. Aug 29;382(6594):833-5.
- Olsen DB**, Stahlhut MW, Rutkowski CA, Schock HB, vanOlden AL, Kuo LC (1999). Non-active site changes elicit broad-based cross-resistance of the HIV-1 protease to inhibitors. *J Biol Chem*. Aug 20;274(34):23699-701.

- Orenstein JM**, Meltzer MS, Phipps T, Gendelman HE (1988). Cytoplasmic assembly and accumulation of human immunodeficiency virus types 1 and 2 in recombinant human colony-stimulating factor-1-treated human monocytes: an ultrastructural study. *J Virol.* Aug;62(8):2578-86.
- Palella FJ Jr**, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD (1998). Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. *N Engl J Med.* Mar 26;338(13):853-60.
- Patel PH**, Jacobo-Molina A, Ding J, Tantillo C, Clark AD Jr, Raag R, Nanni RG, Hughes SH, Arnold E (1995). Insights into DNA polymerization mechanisms from structure and function analysis of HIV-1 reverse transcriptase. *Biochemistry.* Apr 25;34(16):5351-63.
- Paterson DL**, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, Wagener MM, Singh N (2000). Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. *Ann Intern Med.* Jul 4;133(1):21-30.
- Patick AK**, Mo H, Markowitz M, Appelt K, Wu B, Musick L, Kalish V, Kaldor S, Reich S, Ho D, Webber S (1996). Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease. *Antimicrob Agents Chemother.* Feb;40(2):292-7.
- Pavlakis GN**, Schwartz S, D'Agostino D, Felber B (1992). Structure, splicing and regulation of expression of HIV-1: a model for general organisation of lentiviruses and other complex retroviruses. In: *AIDS research reviews.* (W. C. Koff, R. C. Kennedy, and F. Wong-Staal, Eds), pp.41-63. Marcel Dekker, New York.
- Paxton W**, Connor RI, Landau NR (1993). Incorporation of Vpr into human immunodeficiency virus type 1 virions: requirement for the p6 region of gag and mutational analysis. *J Virol.* Dec;67(12):7229-37.
- Peiperl L** (2001). Antiretroviral Resistance Mutations. *HIV Clinical Trials.* 2(4):346-355
- Pelletier H**, Sawaya MR, Kumar A, Wilson SH, Kraut J (1994). Structures of ternary complexes of rat DNA polymerase beta, a DNA template-primer, and ddCTP. *Science.* Jun 24;264(5167):1891-903.
- Perelson AS**, Neumann AU, Markowitz M, Leonard JM, Ho DD (1996). HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. *Science* 271, 1582-86
- Perno CF**, Cozzi-Lepri A, Balotta C, Forbici F, Violin M, Bertoli A, Facchi G, Pezzotti P, Cadeo G, Tositti G, Pasquinucci S, Pauluzzi S, Scalzini A, Salassa B, Vincenti A, Phillips AN, Dianzani F, Appice A, Angarano G, Monno L, Ippolito G, Moroni M, d' Arminio Monforte A (2001). Secondary mutations in the protease region of human immunodeficiency virus and virologic failure in drug-naive patients treated with protease inhibitor-based therapy. *J Infect Dis.* Oct 15;184(8):983-91.

Perrin L, Brun-Venizet F, Loveday C et al. and the European Expert Panel for Resistance Guidelines (1999). Overview of prevalence of HIV drug resistance in antiretroviral inexperienced patients in Europe. *Seventh European Conference on Clinical Aspects and Treatment of HIV infection*, Lisbon, Portugal Abstract 224

Pieniazek D, Rayfield M, Hu DJ, Nkengasong J, Wiktor SZ, Downing R, Biryahwaho B, Mastro T, Tanuri A, Soriano V, Lal R, Dondero T (2000). Protease sequences from HIV-1 group M subtypes A-H reveal distinct amino acid mutation patterns associated with protease resistance in protease inhibitor-naive individuals worldwide. HIV Variant Working Group. *AIDS*. Jul 28;14(11):1489-95.

Popovic M, Sarngadharan MG, Read E, Gallo RC (1984). Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. *Science*. May 4;224(4648):497-500.

Premack BA, Schall TJ (1996). Chemokine receptors: gateways to inflammation and infection. *Nat Med*. Nov;2(11):1174-8. Review.

Preston BD, Poiesz BJ, Loeb LA (1988) Fidelity of HIV-1 reverse transcriptase. *Science* 242:1168-71

Pullen KA, Champoux JJ (1990). Plus-strand origin for human immunodeficiency virus type 1: implications for integration. *J Virol*. Dec;64(12):6274-7.

Reed LJ, Muench HA (1938). A simple method of estimating fifty per cents endpoints. *Am J Hyg*. 27:493

Reil H, Kollmus H, Weidle UH, Hauser H (1993). A heptanucleotide sequence mediates ribosomal frameshifting in mammalian cells. *J Virol*. Sep;67(9):5579-84.

Ren J, Esnouf R, Hopkins A, Ross C, Jones Y, Stammers D, Stuart D (1995). The structure of HIV-1 reverse transcriptase complexed with 9-chloro-TIBO: lessons for inhibitor design. *Structure*. Sep 15;3(9):915-26.

Ribeiro RM, Bonhoeffer S (2000). Production of resistant HIV mutants during antiretroviral therapy. *Proc Natl Acad Sci U S A*. Jul 5;97(14):7681-6.

Rick SW, Topol IA, Erickson JW, Burt SK (1998). Molecular mechanisms of resistance: free energy calculations of mutation effects on inhibitor binding to HIV-1 protease. *Protein Sci*. Aug;7(8):1750-6.

Roberts NA, Martin JA, Kinchington D, Broadhurst AV, Craig JC, Duncan IB, Galpin SA, Handa BK, Kay J, Krohn A, et al (1990). Rational design of peptide-based HIV proteinase inhibitors. *Science*. Apr 20;248(4953):358-61.

Robertson DL, Hahn BH, Sharp PM (1995). Recombination in AIDS viruses. *J Mol Evol*. Mar;40(3):249-59.

Rockstroh JK (1999) In: Gölz, Mayr, Heise, HIV und AIDS, Praxis der Beratung und Behandlung. Urban und Fischer

Rodgers DW, Gamblin SJ, Harris BA, Ray S, Culp JS, Hellmig B, Woolf DJ, Debouck C, Harrison SC (1995). The structure of unliganded reverse transcriptase from the human immunodeficiency virus type 1. *Proc Natl Acad Sci U S A*. Feb 14;92(4):1222-6.

Rogel ME, Wu LI, Emerman M (1995). The human immunodeficiency virus type 1 vpr gene prevents cell proliferation during chronic infection. *J Virol*. Feb;69(2):882-8.

Rosen CA, Sodroski JG, Haseltine WA (1985). Location of cis-acting regulatory sequences in the human T-cell leukemia virus type I long terminal repeat. *Proc Natl Acad Sci USA* 82:6502-6

Rouzine IM, Coffin JM (1999). Search for the mechanism of genetic variation in the pro gene of human immunodeficiency virus. *J Virol*. Oct;73(10):8167-78.

Ruiz N, Nusrat R, Lauenroth-Mai E, Berger D, Walworth C, Bacheler LT, Ploughman L, Tsang P, Labriola D, Echols R, Levy R, the DPC 083-203 Study Team (2002). Study DPC 083-203, a Phase II comparison of 100 and 200 mg once-daily DPC 083 and 2 NRTIs in patients failing a NNRTI-containing regimen. 9th Conference on Retroviruses and Opportunistic Infections (CROI), Seattle, Abstract 6

Sakaguchi K, Zambrano N, Baldwin ET, Shapiro BA, Erickson JW, Omichinski JG, Clore GM, Gronenborn AM, Appella E (1993). Identification of a binding site for the human immunodeficiency virus type 1 nucleocapsid protein. *Proc Natl Acad Sci U S A*. Jun 1;90(11):5219-23.

Salter RD, Howell DN, Cresswell P (1985). Genes regulating HLA class I antigen expression in T-B lymphoblast hybrids. *Immunogenetics* 21:235

Sambrook J, Fritsch EF, Maniatis T (1989). Molecular cloning. A Laboratory Manual. Cold Spring Harbor Laboratory, *Cold Spring Harbor, NY*

Sanger F, Nicklen S, Coulson AR (1992). DNA sequencing with chain-terminating inhibitors. 1977. *Biotechnology*;24:104-8.

Sato H, Tomita Y, Shibamura K, Shiino T, Miyakuni T, Takebe Y (2000). Convergent evolution of reverse transcriptase (RT) genes of human immunodeficiency virus type 1 subtypes E and B following nucleoside analogue RT inhibitor therapies. *J Virol*. Jun;74(11):5357-62.

Schinazi RF, Larder B, Mellors JW (2000). Mutations in retroviral genes associated with drug resistance - 2000-2001. *Intern. Antiv. News*. 5(8):129

Schinazi RF, Lloyd RM Jr, Nguyen MH, Cannon DL, McMillan A, Ilksoy N, Chu CK, Liotta DC, Bazmi HZ, Mellors JW (1993). Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides. *Antimicrob Agents Chemother*. Apr;37(4):875-81.

Schmidt B, Korn K, Walter H (2002). Technologies for measuring HIV-1 drug resistance. *HIV Clin Trials*. May-Jun;3(3):227-36.

Schmidt B, Korn K, Werwein M, Schwingel E, Walter H (2001). Abacavir resistance in vitro and in vivo. *Antiviral Therapy*. 6:S16

Schuetz JD, Connelly MC, Sun D, Paibir SG, Flynn PM, Srinivas RV, Kumar A, Fridland A (1999). MRP4: A previously unidentified factor in resistance to nucleoside-based antiviral drugs. *Nat Med*. Sep;5(9):1048-51

Schuurman R, Brambilla D, de Groot T, Huang D, Land S, Bremer J, Benders I, Boucher CA (2002). Underestimation of HIV type 1 drug resistance mutations: results from the ENVA-2 genotyping proficiency program. *AIDS Res Hum Retroviruses*. Mar 1;18(4):243-8.

Schwartz R, Kazanjian P, Slater L, Hathaway B, Markowitz M, Wheeler D, Goldman M, Drulak M, McCallister S, Mayers D (2002). Resistance to Tipranavir is uncommon in a randomized trial of Tipranavir/Ritonavir (TPV/RTV) in multiple PI-failure patients. 9th Conference on Retroviruses and Opportunistic Infections (CROI), Seattle, Abstract 562-T

Semple M, Loveday C, Weller I, Tedder R (1991). Direct measurement of viraemia in patients infected with HIV-1 and its relationship to disease progression and zidovudine therapy. *J Med Virol*. Sep;35(1):38-45.

Shafer RW, Eisen JA, Merigan TC, Katzenstein DA (1997). Sequence and drug susceptibility of subtype C reverse transcriptase from human immunodeficiency virus type 1 seroconverters in Zimbabwe. *J Virol*. Jul;71(7):5441-8.

Shirasaka T, Kavlick MF, Ueno T, Gao WY, Kojima E, Alcaide ML, Choekijchai S, Roy BM, Arnold E, Yarchoan R, et al (1995). Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides. *Proc Natl Acad Sci U S A*. Mar 14;92(6):2398-402.

Simon F, Mauclore P, Roques P, Loussert-Ajaka I, Muller-Trutwin MC, Saragosti S, Georges-Courbot MC, Barre-Sinoussi F, Brun-Vezinet F (1998). Identification of a new human immunodeficiency virus type 1 distinct from group M and group O. *Nat Med*. Sep;4(9):1032-7.

Simon V, Arasteh K (1999). Resistenzentwicklung. In: *HIV und AIDS, Praxis der Beratung und Behandlung*. Eds. Götz, Mayr, Heise, Urban & Fischer S. 131-38

Simon V (2001). Evolving patterns of HIV-1 resistance to antiretroviral agents in newly infected individuals. 1st IAS Conference on HIV Pathogenesis and Treatment, Buenos Aires, Abstract 122

Smerdon SJ, Jager J, Wang J, Kohlstaedt LA, Chirino AJ, Friedman JM, Rice PA, Steitz TA (1994). Structure of the binding site for nonnucleoside inhibitors of the reverse transcriptase of human immunodeficiency virus type 1. *Proc Natl Acad Sci U S A*. Apr 26;91(9):3911-5.

Sousa R, Rose J, Wang BC (1994). The thumb's knuckle. Flexibility in the thumb subdomain of T7 RNA polymerase is revealed by the structure of a chimeric T7/T3 RNA polymerase. *J Mol Biol*. Nov 18;244(1):6-12.

South TL, Blake PR, Sowder RC 3rd, Arthur LO, Henderson LE, Summers MF (1990). The nucleocapsid protein isolated from HIV-1 particles binds zinc and forms retroviral-type zinc fingers. *Biochemistry*. Aug 28;29(34):7786-9.

Spence RA, Kati WM, Anderson KS, Johnson KA (1995). Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors. *Science*. Feb 17;267(5200):988-93.

Starcich BR, Hahn BH, Shaw GM, McNeely PD, Modrow S, Wolf H, Parks ES, Parks WP, Josephs SF, Gallo RC, et al (1986). Identification and characterization of conserved and variable regions in the envelope gene of HTLV-III/LAV, the retrovirus of AIDS. *Cell*. Jun 6;45(5):637-48.

Steitz TA, Steitz JA (1993). A general two-metal-ion mechanism for catalytic RNA. *Proc Natl Acad Sci U S A*. Jul 15;90(14):6498-502.

Stuhlmann H, Berg P (1992). Homologous recombination of copackaged retrovirus RNAs during reverse transcription. *J Virol* 66:2378-2388

Tang J, James MN, Hsu IN, Jenkins JA, Blundell TL (1978). Structural evidence for gene duplication in the evolution of the acid proteases. *Nature*. Feb 16;271(5646):618-21.

Tantillo C, Ding J, Jacobo-Molina A, Nanni RG, Boyer PL, Hughes SH, Pauwels R, Andries K, Janssen PA, Arnold E (1994). Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. Implications for mechanisms of drug inhibition and resistance. *J Mol Biol*. Oct 28;243(3):369-87. Review.

Terwilliger EF, Cohen EA, Lu YC, Sodroski JG, Haseltine WA (1989). Functional role of human immunodeficiency virus type 1 vpu. *Proc Natl Acad Sci U S A*. Jul;86(13):5163-7.

The EuroGuidelines Group for HIV resistance (2001). Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: recommendations for the European setting. *AIDS*. Feb 16;15(3):309-20.

Tisdale M, Kemp SD, Parry NR, Larder BA (1993). Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. *Proc Natl Acad Sci U S A*. Jun 15;90(12):5653-6.

Toh H, Kikuno R, Hayashida H, Miyata T, Kugimiya W, Inouye S, Yuki S, Saigo K (1985). Close structural resemblance between putative polymerase of a *Drosophila* transposable genetic element 17.6 and pol gene product of Moloney murine leukaemia virus. *EMBO J*. May;4(5):1267-72.

Triques K, Bourgeois A, Vidal N, Mpoudi-Ngole E, Mulanga-Kabeya C, Nzilambi N, Torimiro N, Saman E, Delaporte E, Peeters M (2000). Near-full-length genome sequencing of divergent African HIV type 1 subtype F viruses leads to the identification of a new HIV type 1 subtype designated K. *AIDS Res Hum Retroviruses*. Jan 20;16(2):139-51.

Tural C, Ruiz L, Holtzer C, Schapiro J, Viciana P, Gonzalez J, Domingo P, Boucher C, Rey-Joly C, Clotet B (2002). Clinical utility of HIV-1 genotyping and expert advice: the Havana trial. *AIDS*. Jan 25;16(2):209-18.

Tyndall JD, Reid RC, Tyssen DP, Jardine DK, Todd B, Passmore M, March DR, Pattenden LK, Bergman DA, Alewood D, Hu SH, Alewood PF, Birch CJ, Martin JL, Fairlie DP (2000). Synthesis, stability, antiviral activity, and protease-bound structures of substrate-mimicking constrained macrocyclic inhibitors of HIV-1 protease. *J Med Chem.* Sep 21;43(19):3495-504.

UK Collaborative Group on monitoring the Transmission of HIV drug resistance (2001). Analysis of prevalence of HIV-1 drug resistance in primary infections in the United Kingdom. *BJM.* 322:1087-88

UNAIDS (2001). Report on the Global HIV-Aids Epidemic. Geneva: *UNAIDS* 2001

Vacca JP, Dorsey BD, Schleif WA, Levin RB, McDaniel SL, Darke PL, Zugay J, Quintero JC, Blahy OM, Roth E, et al (1994). L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor. *Proc Natl Acad Sci U S A.* Apr 26;91(9):4096-100.

van Kuppeveld FJ, Melchers WJ, Willemse HF, Kissing J, Galama JM, van der Logt JT (1993). Detection of *Mycoplasma pulmonis* in experimentally infected laboratory rats by 16S rRNA amplification. *J Clin Microbiol.* Mar;31(3):524-7.

Van Vaerenbergh K, Harrer T, Schmit JC, Carbonez A, Fontaine E, Kurowski M, Grunke M, Low P, Rascu A, Schmidt B, Schmitt M, Thoelen I, Walter H, Van Laethem K, Van Ranst M, Desmyter J, De Clercq E, Vandamme AM (2002). Initiation of HAART in drug-naive HIV type 1 patients prevents viral breakthrough for a median period of 35.5 months in 60% of the patients. *AIDS Res Hum Retroviruses.* Apr 10;18(6):419-26.

Varmus H, Swanstrom R (1991). Replication of retroviruses. In Weiss R, Teich N, Varmus H, et al. eds. *RNA tumor viruses: molecular biology of tumor viruses*. Cold Spring Harbour, New York: Cold Spring Harbour Laboratories, 1991:369-512

Volberding PA, Lagakos SW, Koch MA, Pettinelli C, Myers MW, Booth DK, Balfour HH Jr, Reichman RC, Bartlett JA, Hirsch MS, et al (1990). Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases. *N Engl J Med.* Apr 5;322(14):941-9.

von der Helm K (1996). Retroviral proteases: structure, function and inhibition from a non-anticipated viral enzyme to the target of a most promising HIV therapy. *Biol Chem.* Dec;377(12):765-74. Review.

Wain-Hobson S, Sonigo P, Danos O, Cole S, Alizon M (1985). Nucleotide sequence of the AIDS virus, LAV. *Cell.* Jan;40(1):9-17.

Walter H, Schmidt B, Korn K, Vandamme AM, Harrer T, Uberla K (1999). Rapid, phenotypic HIV-1 drug sensitivity assay for protease and reverse transcriptase inhibitors. *J Clin Virol.* Jun;13(1-2):71-80.

Wegner SA, Brodine SK, Mascola JR, Tasker SA, Shaffer RA, Starkey MJ, Barile A, Martin GJ, Aronson N, Emmons WW, Stephan K, Bloor S, Vingerhoets J, Hertogs K, Larder B (2000). Prevalence of genotypic and phenotypic resistance to anti-retroviral drugs in a cohort of therapy-naive HIV-1 infected US military personnel. *AIDS.* May 26;14(8):1009-15.

Willey RL, Maldarelli F, Martin MA, Strebel K (1992). Human immunodeficiency virus type 1 Vpu protein regulates the formation of intracellular gp160-CD4 complexes. *J Virol.* Jan;66(1):226-34.

Winters MA, Coolley KL, Girard YA, Levee DJ, Hamdan H, Shafer RW, Katzenstein DA, Merigan TC (1998). A 6-basepair insert in the reverse transcriptase gene of human immunodeficiency virus type 1 confers resistance to multiple nucleoside inhibitors. *J Clin Invest.* Nov 15;102(10):1769-75.

Wlodawer A, Miller M, Jaskolski M, Sathyanarayana BK, Baldwin E, Weber IT, Selk LM, Clawson L, Schneider J, Kent SB (1989). Conserved folding in retroviral proteases: crystal structure of a synthetic HIV-1 protease. *Science.* Aug 11;245(4918):616-21.

Wöhrl BM, Moelling K (1990). Interaction of HIV-1 ribonuclease H with polypurine tract containing RNA-DNA hybrids. *Biochemistry.* Nov 6;29(44):10141-7.

Wong-Staal F (1991). Human immunodeficiency viruses and their replication. In: *Fundamental Virology*, ed.: Fields BN, Knipe DM et al. Raven Press, Ltd., New York 1991

Wood E, Montaner J, Chan K, Schechter MM, O'Shaughnessy MV, Hogg R (2002). The impact of socioeconomic status and physician experience on survival from HIV-disease since 1996. 9th Conference on Retroviruses and Opportunistic Infections (CROI), Seattle, Abstract 750-W

Xie D, Gulnik S, Gustchina E, Yu B, Shao W, Qoronfleh W, Nathan A, Erickson JW (1999). Drug resistance mutations can effect dimer stability of HIV-1 protease at neutral pH. *Protein Sci.* Aug;8(8):1702-7.

Yamaguchi J, Vallari AS, Swanson P, Bodelle P, Kaptue L, Ngansop C, Zekeng L, Gurtler LG, Devare SG, Brennan CA (2002). Evaluation of HIV type 1 group O isolates: identification of five phylogenetic clusters. *AIDS Res Hum Retroviruses.* Mar 1;18(4):269-82.

Yerly S, Kaiser L, Race, Bru JP, Clavel F, Perrin L (1999). Transmission of antiretroviral drug-resistant HIV-1 variants. *Lancet* 354:729-33

Yerly S, Rakik A, De Loes SK, Hirschel B, Descamps D, Brun-Vezinet F, Perrin L (1998). Switch to unusual amino acids at codon 215 of the human immunodeficiency virus type 1 reverse transcriptase gene in seroconvertors infected with zidovudine-resistant variants. *J Virol.* May;72(5):3520-3.

Yerly S, Vora S, Rizzardi P, Chave JP, Vernazza PL, Flepp M, Telenti A, Battegay M, Veuthey AL, Bru JP, Rickenbach M, Hirschel B, Perrin L (2001). Acute HIV infection: impact on the spread of HIV and transmission of drug resistance. *AIDS.* Nov 23;15(17):2287-92.

Yoshinaga T, Sato A, Fujishita T, Fujiwara T (2002). S-1360: in vitro activity of a new HIV-1 integrase inhibitor in clinical development. 9th Conference on Retroviruses and Opportunistic Infections (CROI), Seattle, Abstract 8

Yu X, Yuan X, Matsuda Z, Lee TH, Essex M (1992). The matrix protein of human immunodeficiency virus type 1 is required for incorporation of viral envelope protein into mature virions. *J Virol.* Aug;66(8):4966-71.

Zekeng L, Gürtler L, Afane Ze E, Sam-Abbenyi A, Mbouni-Essomba G, Mpoudi-Ngolle E, Monny-Lobe M, Tapka JB, Kaptue L (1994). Prevalence of HIV-1 subtype O infection in Cameroon: preliminary results. *AIDS.* Nov;8(11):1626-8.

Zhang YM, Imamichi H, Imamichi T, Lane HC, Falloon J, Vasudevachari MB, Salzman NP (1997). Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites. *J Virol.* Sep;71(9):6662-70.